Lycera is a private biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. Based on its world-class R&D engine, Lycera is advancing clinical candidates from distinct, yet complementary , areas of research, including immune metabolism, cell signaling, and immune cell differentiation. Lycera’s lead product candidate, a novel oral, gut-directed ATPase modulator, designated LYC-30937-EC, for the treatment of inflammatory bowel disease (IBD), completed a Phase I clinical healthy volunteer study in December of 2015. The Company also has a leading position in the development of agonists of RORγ, a master transcription factor, or “master control switch,” with diverse applications in immuno-oncology. In June of 2015, Lycera entered into an exclusive global collaboration with Celgene Corporation to advance Lycera’s proprietary pipeline. As part of the strategic agreement, Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones. During the option period, Lycera retains full control of its R&D programs.
Latest funding size
Time since last funding
|over 2 years|
|InterWest Partners, Clarus Ventures, ARCH Venture Partners, EDF Ventures|